cabozantinib for third line stomach cancer
Interviews and expert commentary tagged “cabozantinib for third line stomach cancer” — the latest oncology research and clinical practice from the Audio Journal of Oncology.
Audio Journal of Oncology
Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib
BARCELONA—Oral cabozantinib “significantly improved” overall survival (OS) and progression free survival (PFS) compared to placebo in patients with advanced hepatocellular carcinoma(HCC) w
15 October 2018
8 mins